CL2021000196A1 - Método de tratamiento de la epilepsia - Google Patents
Método de tratamiento de la epilepsiaInfo
- Publication number
- CL2021000196A1 CL2021000196A1 CL2021000196A CL2021000196A CL2021000196A1 CL 2021000196 A1 CL2021000196 A1 CL 2021000196A1 CL 2021000196 A CL2021000196 A CL 2021000196A CL 2021000196 A CL2021000196 A CL 2021000196A CL 2021000196 A1 CL2021000196 A1 CL 2021000196A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment method
- epilepsy treatment
- epilepsy
- salt
- fenfluramin
- Prior art date
Links
- 206010015037 epilepsy Diseases 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229960001264 benfluorex Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C211/15—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C219/14—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to a carbon atom of a six-membered aromatic ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862711051P | 2018-07-27 | 2018-07-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021000196A1 true CL2021000196A1 (es) | 2021-12-31 |
Family
ID=67551433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021000196A CL2021000196A1 (es) | 2018-07-27 | 2021-01-25 | Método de tratamiento de la epilepsia |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20200030260A1 (enExample) |
| EP (1) | EP3829558B1 (enExample) |
| JP (1) | JP2021530541A (enExample) |
| KR (1) | KR20210061332A (enExample) |
| CN (1) | CN112930175A (enExample) |
| AU (1) | AU2019310600A1 (enExample) |
| BR (1) | BR112021001135A2 (enExample) |
| CA (1) | CA3106031A1 (enExample) |
| CL (1) | CL2021000196A1 (enExample) |
| CO (1) | CO2021002087A2 (enExample) |
| CR (1) | CR20210095A (enExample) |
| EA (1) | EA202190369A1 (enExample) |
| ES (1) | ES2988130T3 (enExample) |
| IL (1) | IL280128A (enExample) |
| MA (1) | MA53329A (enExample) |
| MX (1) | MX2021000987A (enExample) |
| PE (1) | PE20211065A1 (enExample) |
| PH (1) | PH12021550176A1 (enExample) |
| SG (1) | SG11202100682YA (enExample) |
| WO (1) | WO2020023923A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| HRP20250898T1 (hr) | 2015-12-22 | 2025-09-26 | Zogenix International Limited | Pripravci fenfluramina i postupci njihove pripreme |
| WO2017112701A1 (en) | 2015-12-22 | 2017-06-29 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| JP2019526544A (ja) | 2016-08-24 | 2019-09-19 | ゾゲニクス インターナショナル リミテッド | ５−ｈｔ２ｂアゴニストの形成を阻害するための製剤およびその使用方法 |
| US10752623B2 (en) * | 2018-08-31 | 2020-08-25 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors |
| SG11202104378SA (en) | 2018-11-19 | 2021-05-28 | Zogenix International Ltd | Methods of treating rett syndrome using fenfluramine |
| US11897995B2 (en) * | 2019-07-18 | 2024-02-13 | Basf Se | Allophanate based dispersing agent |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| JP2024533015A (ja) * | 2021-09-01 | 2024-09-12 | ゾゲニクス インターナショナル リミテッド | 脱髄性の疾患および病状の処置のためのフェンフルラミン |
| CN118873517A (zh) * | 2024-07-05 | 2024-11-01 | 上海柯西医药科技发展有限公司 | 大麻二酚与5-ht2b受体激动剂的组合的用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL270984A (enExample) | 1960-11-05 | |||
| GB1175516A (en) | 1966-04-15 | 1969-12-23 | Science Union & Cie | New Phenyl-Aminopropane Derivatives and Preparations Containing them |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| PT762877E (pt) * | 1994-06-03 | 2001-08-30 | Thejmde Trust | Arilalquilaminas meta-substituidas e suas aplicacoes terapeuticas e de diagnostico |
| ATE227120T1 (de) | 1997-05-07 | 2002-11-15 | Galen Chemicals Ltd | Vorrichtungen zur intravaginalen verabreichung von testosteron und testosteron- vorläuferverbindungen |
| US6591909B1 (en) | 2001-12-20 | 2003-07-15 | Halliburton Energy Services, Inc. | Whey protein retarder |
| US9549909B2 (en) * | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| EA201992474A3 (ru) * | 2015-02-25 | 2020-05-31 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа | Агонисты 5ht для лечения нарушений |
| JP6668045B2 (ja) * | 2015-05-15 | 2020-03-18 | ゾゲニクス インターナショナル リミテッド | ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト |
| JP2017057188A (ja) * | 2015-09-14 | 2017-03-23 | ゾゲニクス インターナショナル リミテッド | 特別な形態のてんかんの併用療法 |
| GB201715919D0 (en) * | 2017-09-29 | 2017-11-15 | Gw Res Ltd | use of cannabinoids in the treatment of epilepsy |
-
2019
- 2019-07-26 KR KR1020217004603A patent/KR20210061332A/ko not_active Ceased
- 2019-07-26 MX MX2021000987A patent/MX2021000987A/es unknown
- 2019-07-26 EA EA202190369A patent/EA202190369A1/ru unknown
- 2019-07-26 ES ES19750214T patent/ES2988130T3/es active Active
- 2019-07-26 BR BR112021001135-8A patent/BR112021001135A2/pt not_active IP Right Cessation
- 2019-07-26 EP EP19750214.9A patent/EP3829558B1/en active Active
- 2019-07-26 SG SG11202100682YA patent/SG11202100682YA/en unknown
- 2019-07-26 PE PE2021000089A patent/PE20211065A1/es unknown
- 2019-07-26 WO PCT/US2019/043765 patent/WO2020023923A1/en not_active Ceased
- 2019-07-26 JP JP2021503108A patent/JP2021530541A/ja active Pending
- 2019-07-26 US US16/523,568 patent/US20200030260A1/en active Pending
- 2019-07-26 CR CR20210095A patent/CR20210095A/es unknown
- 2019-07-26 CA CA3106031A patent/CA3106031A1/en active Pending
- 2019-07-26 AU AU2019310600A patent/AU2019310600A1/en not_active Abandoned
- 2019-07-26 MA MA053329A patent/MA53329A/fr unknown
- 2019-07-26 CN CN201980049623.9A patent/CN112930175A/zh active Pending
-
2021
- 2021-01-12 IL IL280128A patent/IL280128A/en unknown
- 2021-01-22 PH PH12021550176A patent/PH12021550176A1/en unknown
- 2021-01-25 CL CL2021000196A patent/CL2021000196A1/es unknown
- 2021-02-23 CO CONC2021/0002087A patent/CO2021002087A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL280128A (en) | 2021-03-01 |
| CR20210095A (es) | 2021-06-01 |
| BR112021001135A2 (pt) | 2021-04-20 |
| US20200030260A1 (en) | 2020-01-30 |
| MA53329A (fr) | 2022-03-02 |
| SG11202100682YA (en) | 2021-02-25 |
| KR20210061332A (ko) | 2021-05-27 |
| WO2020023923A1 (en) | 2020-01-30 |
| JP2021530541A (ja) | 2021-11-11 |
| AU2019310600A1 (en) | 2021-02-11 |
| EP3829558B1 (en) | 2024-07-03 |
| EA202190369A1 (ru) | 2021-06-10 |
| CA3106031A1 (en) | 2020-01-30 |
| EP3829558A1 (en) | 2021-06-09 |
| CO2021002087A2 (es) | 2021-04-30 |
| PE20211065A1 (es) | 2021-06-09 |
| EP3829558C0 (en) | 2024-07-03 |
| PH12021550176A1 (en) | 2021-10-11 |
| MX2021000987A (es) | 2021-06-15 |
| CN112930175A (zh) | 2021-06-08 |
| ES2988130T3 (es) | 2024-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021000196A1 (es) | Método de tratamiento de la epilepsia | |
| CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
| CL2020003257A1 (es) | Compuestos antagonistas de pcsk9. | |
| DOP2020000102A (es) | Compuestos útiles para inhibir a cdk7 | |
| CL2013002417A1 (es) | Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. | |
| DOP2022000066A (es) | Moduladores de sting (estimulador de genes de interferón) | |
| CL2017000902A1 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| CL2020000610A1 (es) | Compuestos de bisamida que activan el sarcómero y sus usos. | |
| CL2015001279A1 (es) | Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras. | |
| AR102981A1 (es) | Inhibidores de la necrosis celular y métodos de preparación de los mismos | |
| BR112019007576A2 (pt) | compostos de bifenil sulfonamida para o tratamento de doenças ou transtornos renais | |
| DOP2017000178A (es) | Inhibidores selectivos de bace1 | |
| CO2019005552A2 (es) | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos | |
| CL2018000007A1 (es) | Compuestos inhibidores de la señalización de la vía de notch | |
| AR093705A1 (es) | Depsipeptido y sus usos | |
| GT201700023A (es) | Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias | |
| UY37941A (es) | Derivados de bencimidazol y sus usos | |
| SV2016005313A (es) | Derivados de carboxamida | |
| MX2019008181A (es) | Inhibidores selectivos hdac6, metodos de preparacion y aplicacion de los mismos. | |
| AR112144A1 (es) | Compuestos para el tratamiento del sarcoma | |
| MX2019003545A (es) | Compuestos heterociclicos y uso de los mismos para prevenir o tratar infecciones bacterianas. | |
| CO2018001237A2 (es) | Derivados de apramicina efectivos contra bacterias resistentes a múltiples fármacos y composiciones de los mismos | |
| CO2022008719A2 (es) | Compuestos para modular la actividad de fxr y usos de los mismos | |
| SV2018005701A (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
| CL2020002199A1 (es) | Compuesto de anillo de metillactama y uso farmacéutico del mismo. |